<DOC>
	<DOCNO>NCT02383355</DOCNO>
	<brief_summary>Cardiovascular disease ( CVD ) emerge lead cause morbidity mortality HIVinfected individual . The precise mechanisms underlie increase cardiovascular risk remain elucidated . Platelet hyperreactivity increase platelet-monocyte aggregation ( PMA ) find HIVinfectedpatients may contribute excess cardiovascular risk platelet play key role onset progression atherosclerosis acute cardiovascular event . In addition , HIV-infected individual frequently suffer persistent immune activation inflammation . In crosssectional study investigator recently show individual use regimen contain integrase inhibitor raltegravir reduce platelet hyperreactivity PMA compare antiretroviral regimen . Other recent study show raltegravir associate decrease immune activation . Due inherent limitation cross sectional study , investigator aim expand finding intervention study . The investigator conduct randomize control trial investigator switch patient integrase contain treatment regimen assay possible change platelet function persistent immune activation . Knowledge gather propose study help understand prevent cardiovascular disease patient treat HIV infection reduce platelet hyperreactivity persistent immune activation .</brief_summary>
	<brief_title>Effects Raltegravir Based Regimen Platelet Reactivity , Platelet-monocyte Aggregation Immune Activation</brief_title>
	<detailed_description>Rationale : Cardiovascular disease ( CVD ) emerge lead cause morbidity mortality HIV-infected individual . The precise mechanisms underlie increase cardiovascular risk remain elucidated . Platelet hyperreactivity increase platelet-monocyte aggregation ( PMA ) find HIV-infected patient may contribute excess cardiovascular risk platelet play key role onset progression atherosclerosis acute cardiovascular event . In addition , HIV-infected individual frequently suffer persistent immune activation inflammation . In cross-sectional study investigator recently show individual use regimen contain integrase inhibitor raltegravir reduce platelet hyperreactivity PMA compare antiretroviral regimen . Other recent study show raltegravir associate decrease immune activation . Due inherent limitation cross sectional study , investigator aim expand finding intervention study . Objective : Investigate whether switch non-nucleoside reverse transcriptase inhibitor ( NNRTI ) - protease inhibitor ( PI ) -based regimen raltegravir-based regimen result reduce platelet reactivity , reduce platelet-leukocyte aggregate formation pro-inflammatory status monocyte . Study design : Investigator initiate , single-center , open-label , randomize controlled trial HIV-infected patient use NNRTI- PI-based regimen . Study population : Adult HIV-infected study participant undetectable ( &lt; 40 copies/mL ) viral load receive standard backbone two NRTI 's ( either tenofovir ( TDF ) /emtricitabine ( FTC ) abacavir ( ABC ) /lamivudine ( 3TC ) ) either NNRTI ( efavirenz ( EFV ) rilpivirine ( RPV ) ) boost PI ( Darunavir ( DRV/r ) , atazanavir ( ATZ/r ) Lopinavir ( LPV/r ) ) . After Sample size calculation two group 20 subject enrol . Intervention : Participants randomize ( 1:1 ) continue ART regimen ( `` Continuation group '' ) switch NNRTI PI raltegravir ( `` Switch group '' ) 10 week . Main study parameters/endpoints : Primary parameter : 1 . Platelet reactivity : platelet expression platelet activation marker CD62P ( P-selectin ) activate fibrinogen receptor ( αIIbβ3 ) upon stimulation different platelet agonist . Secondary parameter : 1 . Platelet-leukocyte aggregate ( eg . PMA ) . 2 . Activation marker T cell monocytes . 3 . Soluble ( plasma ) marker platelet monocyte activation .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Male female Documented HIVinfection Age ≥ 18 year Willing comply protocol requirement On stable antiretroviral therapy ( ART ) ≥ 6 month screen Undetectable plasma HIV viral load ( &lt; 50 copies/mL ) least 6 month CD4 cell count &gt; 300 cells/mm3 last measurement Current ART regimen screen consist backbone two NRTI 's ( either TDF/FTC ABC/3TC ) either NNRTI ( EFV RPV ) boost PI ( DRV/r , ATZ/r LPV/r ) regimen &gt; 3 month If female childbearing potential use effective birth control method Use platelet function inhibitor , aspirin adenosine diphosphate ( ADP ) receptor antagonist Known hypersensitivity raltegravir component formulation Using concomitant therapy disallow per summary product characteristic ( SPC ) study drug Signs symptom active ( opportunistic ) infection HIV Active hepatitis B C Estimated glomerular filtration rate ( MDRD ) &lt; 50 ml/min Clinical laboratory evidence significantly decrease hepatic function , define alanine aminotransferase ( ALAT ) level &gt; 2 upper limit normal ( ULN ) History suspect proven virologic failure since ART initiation ( HIV1 RNA `` blip '' le 500 copy per milliliter subsequent suppression allow ) Known genotypic resistance current ART component Prior use single dual NRTIonly regimens , history ART consider highly active current standard . In female , pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Persistent immune activation</keyword>
	<keyword>Platelet hyperreactivity</keyword>
</DOC>